Huoxiang Zhengqi oral liquid for irritable bowel syndrome with diarrhea: a multicenter, double-blind, randomized controlled trial
- 20 November 2025
- journal article
- Published by Elsevier in Phytomedicine
- Vol. 149, 157567
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science and Technology (2018YFC1707407)
This publication has 29 references indexed in Scilit:
- Different therapies of Chinese herbal medicine for diarrhea-predominant irritable bowel syndrome: A network meta-analysis of double-blinded, placebo-controlled trialsJournal of Ethnopharmacology, 2023
- Acupuncture for the Treatment of Diarrhea-Predominant Irritable Bowel SyndromeJAMA Network Open, 2022
- The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysisThe Lancet Gastroenterology & Hepatology, 2021
- Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trialPharmacological Research, 2020
- Randomized controlled trials: significant results—fragile, thoughKidney International, 2017
- Design of Treatment Trials for Functional Gastrointestinal DisordersGastroenterology, 2016
- Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled TrialClinical Gastroenterology and Hepatology, 2015
- The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility IndexJournal of Clinical Epidemiology, 2014
- Primary Endpoints for Irritable Bowel Syndrome Trials: A Review of Performance of EndpointsClinical Gastroenterology and Hepatology, 2007
- Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trialThe Lancet, 2000